Antiproliferative assay |
A549 cells |
25 ug/ml |
20 hrs |
Antiproliferative activity in human A549 cells at 25 ug/ml up to 20 hrs by xCELLigence RTCA SP based cellular impedance analysis |
28570977 |
Antiproliferative assay |
A549 cells |
25 ug/ml |
60 hrs |
Antiproliferative activity in human A549 cells at 25 ug/ml after 60 hrs by xCELLigence RTCA SP based cellular impedance analysis |
28570977 |
Autophagy assay |
NCI-H3122 cells |
25 to 50 uM |
6 hrs |
Inhibition of autophagy in human NCI-H3122 cells assessed as increase in punctate LC3 expression at 25 to 50 uM after 6 hrs by fluorescence microscopic analysis |
25699157 |
Apoptosis assay |
H460 cells |
25 to 75 uM |
24 hrs |
Induction of apoptosis in human H460 cells at 25 to 75 uM after 24 hrs by annexin-V staining-based flow cytometry |
25699157 |
Antiviral assay |
Vero E6 cells |
|
48 h |
IC50 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells)., IC50 = 0.67608 μM. |
32353859 |
Antiproliferative assay |
BxPC3 cells |
|
72 hrs |
Antiproliferative activity against human BxPC3 cells after 72 hrs by SRB method, IC50 = 33 μM. |
25699157 |
Autophagy assay |
H460 cells |
|
24 hrs |
Inhibition of autophagy in human H460 cells assessed as increase in LC3-2 level at IC50 after 24 hrs by immunoblot analysis |
25699157 |
Antiviral assay |
Vero E6 cells |
|
2 days |
Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days, EC50 = 4.17 μM. |
ChEMBL |
Antiviral assay |
Vero E6 cells |
|
3 days |
IC50 determination at MOI 0.004 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in SARS-CoV-2 infected Vero E6 cells, IC50 = 9.21 μM. |
ChEMBL |
Antiviral assay |
Vero E6 cells |
|
3 days |
IC50 determination at MOI 0.01 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in SARS-CoV-2 infected Vero E6 cells, IC50 = 11.17 μM. |
ChEMBL |
Antiviral assay |
Vero E6 cells |
|
2 days |
Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days, EC90 = 25.49 μM. |
ChEMBL |
Function assay |
HEK-Blue cells |
|
|
Antagonist activity at human TLR9 expressed in HEK-Blue cells assessed as reduction in CpGB-induced NF-kappaB levels after 24 hrs by spectrophotometric analysis, IC50 = 0.11 μM. |
30292896 |
Function assay |
HEK-Blue cells |
|
|
Antagonist activity at human TLR7 expressed in HEK-Blue cells assessed as reduction in CL264-induced NF-kappaB levels after 24 hrs by spectrophotometric analysis, IC50 = 0.8 μM. |
30292896 |
Function assay |
HEK293 cells |
|
|
hERG binding assays: Displacement of [3H]-Dofetilide (5 nM final) from hERG membranes obtained from HEK293 cells, Ki = 2.51189 μM. |
32353859 |
Antiviral assay |
Vero E6 cells |
|
|
IC90 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line by measuring infectious viral titer of supernatent from compound-treated Vero E6 cells by Median Tissue Culture Infectious Dose (TCID)50 by the method of Reed and Muench, IC90 = 5.78 μM. |
32353859 |
qHTS assay |
A673 cells |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells |
29435139 |
qHTS assay |
BT-37 cells |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells |
29435139 |
qHTS assay |
SK-N-MC cells |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells |
29435139 |
qHTS assay |
NB-EBc1 cells |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells |
29435139 |
qHTS assay |
LAN-5 cells |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells |
29435139 |